Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $6.7 million.

  • Beam Therapeutics' Other Non-Current Assets rose 163.38% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 163.38%. This contributed to the annual value of $8.1 million for FY2024, which is 659.48% down from last year.
  • Per Beam Therapeutics' latest filing, its Other Non-Current Assets stood at $6.7 million for Q3 2025, which was up 163.38% from $6.6 million recorded in Q2 2025.
  • Beam Therapeutics' Other Non-Current Assets' 5-year high stood at $15.4 million during Q2 2023, with a 5-year trough of $6.2 million in Q2 2024.
  • Its 5-year average for Other Non-Current Assets is $10.4 million, with a median of $9.8 million in 2023.
  • In the last 5 years, Beam Therapeutics' Other Non-Current Assets skyrocketed by 2099.48% in 2023 and then tumbled by 6009.6% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Other Non-Current Assets stood at $12.7 million in 2021, then increased by 0.06% to $12.8 million in 2022, then crashed by 31.64% to $8.7 million in 2023, then decreased by 6.59% to $8.1 million in 2024, then dropped by 18.27% to $6.7 million in 2025.
  • Its Other Non-Current Assets stands at $6.7 million for Q3 2025, versus $6.6 million for Q2 2025 and $6.6 million for Q1 2025.